Intellipharmaceutics International (IPCI – Snapshot Report) announced that it has technologically upgraded its Rexista oxycodone development program to prevent overdose when tablets in excess of the prescribed dose are swallowed. Patents pending with the U.S. Patent and Trademark office cover the company’s new platform technology, PODRAS. The abuse-deterrent oxycodone is being developed to treat moderate-to-severe pain in situations requiring long-term use of an opioid analgesic.
Intellipharmaceutics stated that following the enhancement, its abuse-deterrent technology can distinguish Rexista from other similar technologies. Intellipharmaceutics further stated that the advanced technology can be applied to many other drugs which have the possibility of being consumed in excess of the prescribed dose either intentionally or unintentionally and can prove to be harmful. Rexista has performed well in pre-clinical trials. Intellipharmaceutics intends to commence clinical studies on Rexista in Canada and the U.S. shortly on the basis of its PODRAS platform technology.
We note that even the FDA has called for a more effective abuse deterrence-technology through a draft guidance issued last year. The FDA had stated at that time that the existing abuse deterrent technologies fail to prevent the most common form of abuse – swallowing multiple tablets for a euphoric feeling.
The new technology from Intellipharmaceutics holds great promise and should go a long way in preventing overdose and efficiently managing pain. Consequently, investor focus will remain on the performance of the new technology in the upcoming clinical studies on Rexista.
Intellipharmaceutics carries a Zacks Rank #4 (Sell). Better-ranked companies in the health care space are Gilead Sciences (GILD – Analyst Report), Amgen (AMGN – Analyst Report) and Endo International (ENDP – Analyst Report). All the three stocks sport a Zacks Rank #1 (Strong Buy).